{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:49:15Z","timestamp":1777420155644,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T00:00:00Z","timestamp":1409097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:p>Opioid abuse in the United States increased significantly over the past decade, leading to opioid-related deaths. Approval of Zohydro ER, a product that lacks an abuse-deterrent formulation, has provoked media controversy and aggressive legislative action from multiple stakeholders. Only the American Academy of Pain Management has released a position statement on this medication, and individual opinion varies. Additional single-entity extended-release hydrocodone formulations are in the pipeline, and Zohydro ER\u2019s limited clinical utility may make the controversy associated with its approval a moot point. As with other opioids, providers will need to assess individual patient risk versus benefit when prescribing Zohydro ER.<\/jats:p>","DOI":"10.1177\/1060028014543174","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T18:38:02Z","timestamp":1409164682000},"page":"1362-1365","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Extended-Release Hydrocodone"],"prefix":"10.1177","volume":"48","author":[{"given":"Anne E.","family":"Schweighardt","sequence":"first","affiliation":[{"name":"St John Fisher College, Wegmans School of Pharmacy, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine M.","family":"Juba","sequence":"additional","affiliation":[{"name":"St John Fisher College, Wegmans School of Pharmacy, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,8,27]]},"reference":[{"key":"bibr1-1060028014543174","unstructured":"Substance Abuse and Mental Health Services Administration. Results From the 2012 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. http:\/\/www.samhsa.gov\/data\/NSDUH\/2012SummNatFindDetTables\/NationalFindings\/NSDUHresults2012.htm#ch2.4. Accessed June 13, 2014."},{"key":"bibr2-1060028014543174","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.272"},{"key":"bibr3-1060028014543174","unstructured":"Centers for Disease Control and Prevention. Policy impact: prescription painkiller overdoses. http:\/\/www.cdc.gov\/homeandrecreationalsafety\/rxbrief\/. Accessed June 13, 2014."},{"key":"bibr4-1060028014543174","first-page":"1","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bibr5-1060028014543174","unstructured":"Food and Drug Administration. FDA background material: NDA 202880. Zohydro ER (hydrocodone) for the management of moderate to severe chronic pain. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee\/UCM330683.pdf. Accessed June 13, 2014."},{"key":"bibr6-1060028014543174","volume-title":"(Hydrocodone bitartrate) extended-release capsules [product information]","author":"Zohydro\u2122 ER","year":"2013"},{"key":"bibr7-1060028014543174","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12377"},{"key":"bibr8-1060028014543174","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S33062"},{"key":"bibr9-1060028014543174","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007758"},{"key":"bibr10-1060028014543174","unstructured":"State Attorneys General. A communication from the chief legal officers. http:\/\/www.oag.state.md.us\/Press\/Zohydro.pdf. Accessed June 13, 2014."},{"key":"bibr11-1060028014543174","unstructured":"State Attorneys General. A communication from the chief legal officers. http:\/\/ag.ky.gov\/pdf_news\/sebelius-zohydro-letter.pdf. Accessed June 13, 2014."},{"key":"bibr12-1060028014543174","unstructured":"Congress of the United States. Letter to Honorable Kathleen Sebelius. http:\/\/lynch.house.gov\/sites\/lynch.house.gov\/files\/Letter%20to%20Secretary%20Sebelius%20on%20FDA%20Zohydro%20approval.pdf. Accessed June 13, 2014."},{"key":"bibr13-1060028014543174","unstructured":"Library of Congress. S.2134: Act to ban Zohydro\u00ae. http:\/\/beta.congress.gov\/bill\/113th-congress\/senate-bill\/2134. Accessed June 13, 2014."},{"key":"bibr14-1060028014543174","unstructured":"The Boston Globe. Mass. limits use of the potent painkiller Zohydro\u00ae. http:\/\/www.bostonglobe.com\/metro\/2014\/04\/22\/governor-deval-patrick-administration-enacts-new-restrictions-zohydro\/GpIZM4OUOgZg7cWEI8XV5N\/story.html. Accessed June 13, 2014."},{"key":"bibr15-1060028014543174","unstructured":"Massachusetts Board of Registration in Medicine. 243 CMR 2.07(25): prescribing hydrocodone-only extended-release medication. http:\/\/www.mass.gov\/eohhs\/docs\/borim\/emer-gency-regulation.pdf. Accessed June 13, 2014."},{"key":"bibr16-1060028014543174","unstructured":"State of Vermont Office of the Secretary of State. Zohydro\n                      \u00ae\n                      emergency rule. http:\/\/healthvermont.gov\/regs\/documents\/hydrocodone_emergency_rule. Accessed June 13, 2014.https:\/\/www.sec.state.vt.us\/media\/474524\/Zohydro-Memo-and-Rules.pdf."},{"key":"bibr17-1060028014543174","unstructured":"American Academy of Pain Management. American Academy of Pain Management statement on extended-release hydrocodone (Zohydro ER\u00ae). http:\/\/www.aapainmanage.org\/academy-in-the-news\/american-academy-of-pain-manageme-nt-releases-statement-on-extended-release-hydrocodone\/. Ac-cessed June 13, 2014."},{"key":"bibr18-1060028014543174","unstructured":"Purdue Pharma LP. Purdue Pharma L.P. submits NDA for once-daily hydrocodone bitartrate extended-release tablets formulated to incorporate abuse-deterrent properties. http:\/\/www.purduepharma.com\/news-media\/2014\/04\/purdue-pharma-submits-nda-for-once-daily-hydrocodone-bitartrate-extended-release-tablets\/. Accessed June 13, 2014."},{"key":"bibr19-1060028014543174","unstructured":"Teva Pharmaceutical Industries Ltd. Teva reports positive results from pivotal phase III study to evaluate hydrocodone bitartrate extended-release tablets (CEP-33237) for moderate to severe chronic low back pain. http:\/\/www.tevapharm.com\/Media\/News\/Pages\/2014\/1924140.aspx?year=2014. Accessed June 13, 2014."},{"key":"bibr20-1060028014543174","unstructured":"Egalet Corporation. Developing abuse-deterrent opioids pipeline. http:\/\/www.egalet.com\/products-and-pipeline\/pipe-line\/. Accessed June 13, 2014."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028014543174","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028014543174","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028014543174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:16Z","timestamp":1777374796000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028014543174"}},"subtitle":["The Devil in Disguise or Just Misunderstood?"],"short-title":[],"issued":{"date-parts":[[2014,8,27]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1177\/1060028014543174"],"URL":"https:\/\/doi.org\/10.1177\/1060028014543174","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,27]]}}}